BEL 20 Gains 0.24% as Melexis Supports Brussels Market
Published on 11/12/2026 at 18:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBEL 20 closes higher in Brussels
- The BEL 20 stood at 6,115.09 points at 17:58 Berlin time on Thursday, November 12, 2026, up 0.24 percent from the previous close.
- Melexis and healthcare stocks supported the index, while KBC weakened after quarterly results drew a cautious assessment.
- The move followed a previous close of 6,100.48 points, according to Euronext.
The BEL 20 finished Thursday's Brussels session higher, with the index standing at 6,115.09 points at 17:58 Berlin time on November 12, 2026. That was a gain of 14.61 points, or 0.24 percent, from the previous Brussels close of 6,100.48 points.
The post-session reading and the previous close are shown in the Beursduivel market liveblog. The comparison level is also consistent with the historical data on Euronext's BEL 20 page, which lists 6,100.48 points as the November 11 close.
Melexis and healthcare support index
Trading in Brussels was supported by Melexis, argenx and UCB, according to the Beursduivel report. Melexis was a particular focus after KBC Securities raised its recommendation from Hold to Accumulate while leaving its price target at 75.00 euros. The report said the technology stock led the main index during the session.
Healthcare shares also contributed to the positive tone. UCB and argenx were reported among the stronger BEL 20 constituents, helping offset weakness elsewhere in the index. The overall advance remained limited, however, with the benchmark only modestly above Wednesday's close.
KBC results weigh on financials
KBC was a notable drag. The bank reported higher third-quarter net interest income and earnings per share, but the figures were described as slightly below expectations. KBC maintained the outlook it had raised with its first-half results in August, while Citi saw limited reason for enthusiasm in the numbers. The share price fell during the session, weighing on the financial component of the BEL 20.
For investors, Thursday's move points to a mixed sector picture rather than a broad-based surge. Positive momentum in selected technology and healthcare names was partly offset by pressure on a major financial constituent. The BEL 20 therefore closed above the previous session's level but remained sensitive to company-specific results and analyst interpretations.
Further BEL 20 coverage is available on the BEL 20 topic page.
